Literature DB >> 10078637

Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52.

B P O'Neill1, C H Wang, J R O'Fallon, J D Colgan, J D Earle, R L Krigel, L D Brown, W L McGinnis.   

Abstract

PURPOSE: We herein report updated survival and toxicity data on the entire cohort of 53 eligible patients treated on North Central Cancer Treatment Group (NCCTG) protocol 86-72-52, which is now closed. METHODS AND MATERIALS: An initial report was published in this journal in 1995. No substantive changes in the conclusions of that report were identified in this analysis. Median survival was 9.6 months for the entire cohort; median survival for the 20 patients who completed the prescribed protocol treatment was 20.7 months. The hematologic and non-hematologic toxicity distributions are virtually the same as those reported in the original paper.
RESULTS: Results are given for the entire group and for subsets defined by age < or = 60 versus > 60 years, and < 70 versus > or = 70 years of age.
CONCLUSIONS: No significant differences were observed in any of the outcome variables by age group. There was, however, a nonsignificant suggestion of poorer outcome in those who were > 60 years of age.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10078637     DOI: 10.1016/s0360-3016(98)00450-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51.

Authors:  Ellen R McPhail; Mark E Law; Paul A Decker; Brian P O'Neill
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

2.  Primary Central Nervous System Lymphoma.

Authors:  Denise M. Damek
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 3.  Updates on Primary Central Nervous System Lymphoma.

Authors:  Lauren R Schaff; Christian Grommes
Journal:  Curr Oncol Rep       Date:  2018-02-28       Impact factor: 5.075

4.  Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone.

Authors:  B P O'Neill; T M Habermann; T E Witzig; M Rodriguez
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

5.  CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.

Authors:  Nadia N Laack; Brian Patrick O'Neill; Karla V Ballman; Judith Rich O'Fallon; Xiomara W Carrero; Paul J Kurtin; Bernd W Scheithauer; Paul D Brown; Thomas M Habermann; Joseph P Colgan; Mark R Gilbert; Roland B Hawkins; Roscoe F Morton; Harry E Windschitl; Tom R Fitch; Eduardo R Pajon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

6.  Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.

Authors:  Kristoph Jahnke; Agnieszka Korfel; Julia Komm; Nikolaos E Bechrakis; Harald Stein; Eckhard Thiel; Sarah E Coupland
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-16       Impact factor: 3.117

Review 7.  Primary CNS Lymphoma.

Authors:  Christian Grommes; Lisa M DeAngelis
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

8.  Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.

Authors:  Andrés J M Ferreri; Teresa Calimeri; Maurilio Ponzoni; Flavio Curnis; Gian Marco Conte; Eloise Scarano; Eltjona Rrapaj; Daniela De Lorenzo; Dario Cattaneo; Federico Fallanca; Alessandro Nonis; Marco Foppoli; Paolo Lopedote; Giovanni Citterio; Letterio S Politi; Marianna Sassone; Piera Angelillo; Elena Guggiari; Sara Steffanoni; Vittoria Tarantino; Fabio Ciceri; Claudio Bordignon; Nicoletta Anzalone; Angelo Corti
Journal:  Blood Adv       Date:  2020-08-11

9.  Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.

Authors:  Kristoph Jahnke; Leslie L Muldoon; Csanad G Varallyay; Seth J Lewin; Robert D Brown; Dale F Kraemer; Carole Soussain; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2009-01-21       Impact factor: 12.300

10.  Primary central nervous system lymphoma in Japan 1995-1999: changes from the preceding 10 years.

Authors:  Yuta Shibamoto; Emiko Tsuchida; Kaori Seki; Natsuo Oya; Masatoshi Hasegawa; Yukihiro Toda; Mitsuhiro Takemoto; Minako Sumi; Jun-ichi Hiratsuka; Masahiko Oguchi; Masako Hosono; Shigeo Yasuda; Mitsuharu Sougawa; Yoshihisa Kakutoh; Naofumi Hayabuchi
Journal:  J Cancer Res Clin Oncol       Date:  2004-03-18       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.